Could a vaccine stop lung cancer before it starts?
NCT ID NCT04298606
First seen Apr 07, 2026 · Last updated May 05, 2026 · Updated 3 times
Summary
This early-phase trial tested a vaccine called CIMAvax-EGF in 20 people at high risk for lung cancer or survivors at risk of recurrence. The vaccine works by helping the body make antibodies against a protein (EGF) that can fuel cancer growth. Researchers measured immune response, side effects, and molecular changes to see if the vaccine might prevent lung cancer from developing or returning.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Conditions
Explore the condition pages connected to this study.